neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launc
Company profile
Ticker
NURO
Exchange
Website
CEO
Shai Gozani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43308180
NURO stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
27 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K/A
Entry into a Material Definitive Agreement
27 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Feb 24
8-K
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
22 Feb 24
8-K
NeuroMetrix Announces One-for-Eight Reverse Stock Split
20 Nov 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
NeuroMetrix Reports Q3 2023 Business Highlights
26 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
20 Oct 23
DEF 14A
Definitive proxy
11 Sep 23
Transcripts
NURO
Earnings call transcript
2023 Q4
22 Feb 24
NURO
Earnings call transcript
2023 Q3
26 Oct 23
NURO
Earnings call transcript
2023 Q2
27 Jul 23
NURO
Earnings call transcript
2023 Q1
3 May 23
NURO
Earnings call transcript
2022 Q4
23 Feb 23
NURO
Earnings call transcript
2022 Q3
20 Oct 22
NURO
Earnings call transcript
2022 Q2
21 Jul 22
NURO
Earnings call transcript
2022 Q1
26 Apr 22
NURO
Earnings call transcript
2021 Q4
27 Jan 22
NURO
Earnings call transcript
2021 Q3
21 Oct 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.46 mm | 1.46 mm | 1.46 mm | 1.46 mm | 1.46 mm | 1.46 mm |
Cash burn (monthly) | 134.13 k | 25.95 k | 653.63 k | 512.57 k | 687.29 k | 509.78 k |
Cash used (since last report) | 803.05 k | 155.39 k | 3.91 mm | 3.07 mm | 4.11 mm | 3.05 mm |
Cash remaining | 657.51 k | 1.31 mm | -2.45 mm | -1.61 mm | -2.65 mm | -1.59 mm |
Runway (months of cash) | 4.9 | 50.3 | -3.8 | -3.1 | -3.9 | -3.1 |
Institutional ownership, Q3 2023
23.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 4 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 205.15 mm |
Total shares | 462.05 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Topline Capital Management | 144.65 k | $0.00 |
Vanguard | 111.85 k | $80.13 mm |
Geode Capital Management | 64.75 k | $45.97 mm |
BLK Blackrock | 40.59 k | $29.08 mm |
Renaissance Technologies | 30.06 k | $22.00 k |
Citadel Advisors | 28.12 k | $19.96 mm |
STT State Street | 18.17 k | $12.90 mm |
NTRS Northern Trust | 11.06 k | $7.92 mm |
Advisor | 4.00 k | $2.86 mm |
Tower Research Capital | 3.90 k | $2.79 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Feb 24 | Thomas T Higgins | Common Stock | Payment of exercise | Dispose F | No | No | 3.03 | 70 | 212.10 | 8,053 |
2 Feb 24 | Thomas T Higgins | Common Stock | Option exercise | Acquire M | No | No | 3.03 | 498 | 1.51 k | 8,123 |
2 Feb 24 | Thomas T Higgins | RSU Common Stock | Option exercise | Dispose M | No | No | 3.03 | 498 | 1.51 k | 2,489 |
2 Feb 24 | Gozani Shai | Common Stock | Payment of exercise | Dispose F | No | No | 3.03 | 94 | 284.82 | 10,424 |
2 Feb 24 | Gozani Shai | Common Stock | Option exercise | Acquire M | No | No | 3.03 | 636 | 1.93 k | 10,518 |
2 Feb 24 | Gozani Shai | RSU Common Stock | Option exercise | Dispose M | No | No | 3.03 | 636 | 1.93 k | 3,178 |
1 Jan 24 | Thomas T Higgins | Common Stock | Payment of exercise | Dispose F | No | No | 3.6 | 68 | 244.80 | 7,625 |
1 Jan 24 | Thomas T Higgins | Common Stock | Option exercise | Acquire M | No | No | 3.6 | 469 | 1.69 k | 7,693 |
1 Jan 24 | Thomas T Higgins | RSU Common Stock | Option exercise | Dispose M | No | No | 3.6 | 469 | 1.69 k | 5,156 |
1 Jan 24 | Gozani Shai | Common Stock | Payment of exercise | Dispose F | No | No | 3.6 | 74 | 266.40 | 9,882 |
News
NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
13 Mar 24
NeuroMetrix Q4 EPS $(1.43) Down From $(0.73) YoY, Sales $1.32M Down From $1.85M YoY
22 Feb 24
Earnings Scheduled For February 22, 2024
22 Feb 24
NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value
13 Feb 24